24/7 Wall St. has put together a preview of Square, Valeant Pharmaceuticals and some of the other top companies reporting their latest results in the coming week.
Pharmaceutical maker Mylan missed analysts' consensus estimate for earnings and revenue. Additional guidance is mixed, causing shares first to fall then to rise. Which direction is more appropriate?
Paul Ausick Most of the earnings season has come and gone but there are still some major companies posting results this week.
Wednesday was a flat day for the U.S. markets although all major averages hit record all-time highs in the session. Crude oil continued to fall, this time below $50, and it looks…
Finally some good news out of Mylan, which potentially is bringing the shares back to about even for 2017.
Chris Lange 24/7 Wall St. has collected several catalysts that are coming up in October for biotech and pharmaceutical companies.
The top analyst upgrades, downgrades and other research calls from Tuesday include Alibaba, Best Buy, Deere, Jinko Solar, Motorola Solutions, Mylan, Redfin and VMware.
Monday was an incredible day for the U.S. broad markets with each index posting an incredible gain on the day. In particular the S&P 500 saw a gain in each one of…
Teva, Mylan, Ensco, and Chesapeake Energy all posted new 52-week lows on Wednesday.
Mylan released its most recent quarterly earnings report before the markets opened on Wednesday. Unfortunately, the earnings and guidance weren't strong enough to hold up the firm and as a result shares…
Chris Lange Teva, Chesapeake Energy, Mylan, and Zynerba all posted new 52-week lows on Monday.
24/7 Wall St. has put together a preview of a few major companies scheduled to report their quarterly results this coming week.
Tuesday was a very strong day for the U.S. broad markets canceling out what was a sluggish Monday. There were green arrows practically everywhere with only a few exceptions, notably in telecom…
Chris Lange 24/7 Wall St. has put together a preview of Disney, Valeant Pharmaceuticals and a other major companies scheduled to report their quarterly results this coming week.
As of the start of May of 2017, just 21 members of the S&P 500 Index were valued at less than 10 times expected earnings per share.
